Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Enterprise Value (2019 - 2025)

BridgeBio Pharma's Enterprise Value history spans 7 years, with the latest figure at -$6.8 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 98.07% year-over-year to -$6.8 million; the TTM value through Dec 2025 reached $10.6 million, up 103.03%, while the annual FY2025 figure was -$6.8 million, 98.07% up from the prior year.
  • Enterprise Value for Q4 2025 was -$6.8 million at BridgeBio Pharma, up from -$635.6 million in the prior quarter.
  • Across five years, Enterprise Value topped out at $10.0 million in Q1 2025 and bottomed at -$917.8 million in Q1 2021.
  • The 5-year median for Enterprise Value is -$454.1 million (2023), against an average of -$480.0 million.
  • The largest YoY upside for Enterprise Value was 102.15% in 2025 against a maximum downside of 88.21% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$390.5 million in 2021, then decreased by 3.28% to -$403.3 million in 2022, then decreased by 5.03% to -$423.6 million in 2023, then grew by 17.47% to -$349.6 million in 2024, then soared by 98.07% to -$6.8 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Enterprise Value are -$6.8 million (Q4 2025), -$635.6 million (Q3 2025), and -$747.0 million (Q2 2025).